Recombinant BLV Vaccine Mutations for Safety and Efficacy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing vaccines against bovine leukemia virus (BLV) face issues of pathogenicity, inadequate efficacy, and short-term protection, with previously developed attenuated BLV proviruses still posing risks and providing insufficient immunity.
Innovation Solution
Development of recombinant attenuated BLV proviruses with specific mutations in the nucleic acid sequence encoding the YXXL signalling motif and the X region, combined with mutations in G4 and R3, which restrict propagation and enhance safety while maintaining infectivity, leading to a strong immune response and long-term protection.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If chemically inactivated BLV or BLV subunit vaccines are used, then safety is improved, but efficacy is inadequate with only low fraction of vaccinated animals protected
Solution Approach 1:
The patent applies parameter changes by introducing specific mutations in the BLV nucleic acid sequence, particularly in the env gene encoding envelope proteins and the X region encoding regulatory proteins. These mutations modify viral parameters to reduce pathogenicity while preserving immunogenicity, achieving both safety and efficacy simultaneously
Solution Approach 2:
The patent uses an intermediary approach by employing a recombinant BLV virus as a live vaccine that serves as a bridge between inactivated vaccines (safe but weak) and wild-type virus (effective but dangerous). The attenuated recombinant virus provides strong immunity while maintaining safety through controlled mutations
2Reliability
If recombinant vaccinia virus or DNA vaccines are used, then immunogenicity is improved, but persistence is poor with rapid decrease of immune protection
Solution Approach 1:
The patent applies self-service by designing a live attenuated viral vaccine that utilizes the virus's own replication machinery to persist and maintain immune protection. The vaccine virus replicates within host cells, providing continuous antigen expression and sustained immunity without requiring complex adjuvants or booster formulations
Solution Approach 2:
The patent employs dynamics by creating a vaccine that adapts to the host immune system over time. The live virus dynamically interacts with host cells, maintaining presence and immune stimulation throughout the protection period, rather than being a static formulation that degrades
3Reliability
If previously developed attenuated BLV proviruses are used, then pathogenicity is reduced, but protection efficacy remains insufficient
Solution Approach 1:
The patent applies segmentation by dividing the BLV genome into functional regions and introducing mutations in specific segments (env gene and X region) that independently control different aspects of viral behavior. This allows selective attenuation of pathogenicity while preserving immunogenicity
Data Source
AI summary
The invention relates to recombinant bovine leukemia viruses that have an attenuated phenotype and comprise a combination of at least two specific mutations. The invention also provides recombinant nucleic acids encoding such viruses, vectors comprising such nucleic acids, and host cells comprising such nucleic acids or vectors. The recombinant attenuated BLV viruses, recombinant nucleic acids, vectors and host cells allow for the preparation of improved vaccines, in particular vaccines suitable for the prophylactic treatment of BLV-associated diseases in subjects. The invention further provides methods for treating BLV-associated diseases in subjects and pharmaceutical compositions suitable for use in these methods.